Association of candidate protein markers with response and development of irAEs after pembrolizumab treatmenta
| Group A (n = 6) | Group B (n = 6) | Group C (n = 8) | Group D (n = 4) | |
|---|---|---|---|---|
| No response | No response | +response | + response | |
| Protein | No toxicity | + toxicity | + toxicity | No toxicity |
| PD-1 | Increased in 2 patients | Increased in 5 patients | Increased in 4 patients | Increased in 2 patients |
| TSHB | Decreased in 3 patients | Decreased in 3 patients | ||
| Increased in 1 patient | ||||
| NT-proBNP | Increased in 1 patient | Decreased in 2 patients | Decreased in 1 patient | |
| Increased in 1 patient | ||||
| CASP-3 | Increased in 2 patients | |||
| Il-17C | Decreased in 2 patients | Increased in 1 patient | ||
| PMVK | Increased in 2 patients | Decreased in 1 patient | Increased in 1 patient | |
| Decreased in 1 patient | ||||
| PTPN1 | Increased in 2 patients | Decreased in 1 patient | ||
| FKBP5 | Increased in 2 patients | Decreased in 1 patient | ||
| Decreased in 1 patient |
↵aIncreased or decreased is defined as a 4-fold or higher concentration change in the post treatment sample, as compared with the pretreatment sample. For more details see text.